The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6 and can bind to a S1 subunit of SARS-CoV-2, or a antibody fragment of the antibody.

Keywords
CELLS YEASTS FUNGI FOOD ENRICHMENT VECTORS GM MICROORGANISMS GMO GENE EXPRESSION GENE TRANSFER GENES MONOCLONAL ANTIBODIES BACTERIA PROTEINS IMMUNOGLOBULINS AMINO ACIDS RECOMBINEERING FERMENTATION PRODUCTS GENETIC ENGINEERING
You do not currently have access to this content.